Cumberland Pharmaceuticals Inc. (CPIX) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $4.69 (+7.82% 1D, market cap $65.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, CPIX ranks #590 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPIX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 85.0%, and ROIC of -16.4%. By comparison, GOSS (Gossamer Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $65.4M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E 7.5x, ROIC 26.6%, cap $64.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
Per CPIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001087294), Cumberland Pharmaceuticals Inc. generated $44.5M in revenue (+17.6% YoY), -$2.8M in net income, and $4.8M in free cash flow against $76.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 55% Net Buy • Cannibal Buyback (-0.96% YoY Shares)
FRED Regime × Technicals: 38% of 52W Range • RSI-14 at 35.3 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While CPIX currently carries a cautious 38/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.12) and Max Pain ($4.92) forces dealer call-delta covering toward $9.74.
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.96% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cumberland Pharmaceuticals Inc. (CPIX) surged +7.82% to $4.69, trading at 38% of its 52-week range ($1.85 – $9.28). Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.
2026-10-28. The following slide deck was published by Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals is now a clinical-stage company focused on ifetroban for DMD cardiomyopathy. Read why CPIX stock is a hold.
Cumberland Pharmaceuticals (NASDAQ:CPIX) said it plans to begin a rolling New Drug Application submission for Dyscorban, its ifetroban candidate for cardiomyopathy associated with Duchenne muscular dystrophy, after the U
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on its ifetroban product
Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by 14.41% to
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on its
Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC) shares rose
Investing.com -- Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) shares fell 11% in after-hours trading Friday following the release of top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patie
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from its Phase 2a ASSIST-SSc
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CPIX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CPIX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Cumberland Pharmaceuticals Inc. (CPIX) ranks #590 by composite RQD confidence (38/100, grade D-) and #718 by equity capitalization ($65.2M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. SPRO currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with CPIX at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CPIX
ACTIVE
Cumberland Pharmaceuticals Inc. | D- | 38/100 | — | 85.0% | -16.4% | +7.82% | $65.2M | Benchmark Subject |
| GOSS Gossamer Bio Inc. | E | 33/100 | — | — | -35.0% | -2.90% | $65.4M | /goss-vs-cpix → |
| SPRO Spero Therapeutics Inc. | D- | 43/100 | 7.5x | — | 26.6% | -4.50% | $64.6M | /spro-vs-cpix → |
| FBIO Fortress Biotech Inc. | D- | 39/100 | — | 66.9% | -35.0% | -4.00% | $66.7M | /fbio-vs-cpix → |
| RNXT RenovoRx Inc. | E | 31/100 | — | 70.9% | -35.0% | -10.74% | $67.2M | /rnxt-vs-cpix → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cumberland Pharmaceuticals Inc. (CPIX) reported GAAP revenue of $44.5M (+17.6% vs. FY2024 revenue of $37.9M , and +12.6% cumulative change since FY2023) , GAAP net income of -$2.8M, operating cash flow of $4.9M, and free cash flow of $4.8M (+812.4% YoY). On the balance sheet, CPIX closed FY2025 with $76.8M in total assets against $0 in total debt (Altman Z-Score: 0.72, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $44.5M | -$2.8M | $4.9M | $4.8M | $76.8M | — |
| FY2024 (FY) | 2024-12-31 | $37.9M | -$6.5M | -$612.2K | -$678.6K | $75.6M | — |
| FY2023 (FY) | 2023-12-31 | $39.6M | -$6.3M | $6.1M | $6.1M | — | — |
As of 2026-11-02, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $4.69 (+7.82% 1D, market cap $65.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, CPIX ranks #590 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPIX carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 85.0%, and ROIC of -16.4%. By comparison, GOSS (Gossamer Bio Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $65.4M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E 7.5x, ROIC 26.6%, cap $64.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
Per CPIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001087294), Cumberland Pharmaceuticals Inc. generated $44.5M in revenue (+17.6% YoY), -$2.8M in net income, and $4.8M in free cash flow against $76.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
CPIX last traded at $4.69 (+7.82% on volume of 128,962 shares), positioning the stock -34.13% below its 50-day simple moving average ($7.12) and -15.04% below its 200-day simple moving average ($5.52). Across its 52-week range of $1.85 to $9.28, CPIX sits at the 38.2% percentile with a 14-day RSI of 35.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.10 to $5.28).
Why CPIX Stock surged +7.82% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).